Surveillance for rotavirus in Argentina

被引:73
作者
Bok, K
Castagnaro, N
Borsa, A
Nates, S
Espul, C
Fay, O
Fabri, A
Grinstein, S
Miceli, I
Matson, DO
Gómez, JA
机构
[1] Inst Nacl Enfermedades Infecciosas, Lab Gastroenteritis Virales, ANLIS Dr Carlos G Malbran, Dept Virol, RA-1281 Buenos Aires, DF, Argentina
[2] Natl Univ Tucuman, Luis C Verna Inst Virol, San Miguel De Tucuman, Argentina
[3] Sor Maria Ludovica Childrens Hosp, Virol Lab, La Plata, Argentina
[4] Natl Univ Cordoba, JM Vanella Virol Inst, Cordoba, Argentina
[5] Cent Hosp Mendoza, Secc Virol Sect, Mendoza, Argentina
[6] Publ Hlth Technol Ctr, Rosario, Argentina
[7] Reg Inst Med, Resistencia, Argentina
[8] Childrens Hosp, Virol Lab, Buenos Aires, DF, Argentina
[9] Minist Hlth, Epidemiol Direct, Buenos Aires, DF, Argentina
[10] Childrens Hosp Kings Daughters, Ctr Pediat Res, Norfolk, VA USA
关键词
rotavirus; epidemiology; genotypes; serotype; VP4; VP7;
D O I
10.1002/jmv.2020
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Group A rotaviruses are the major cause of severe gastroenteritis in young children worldwide. Because rotavirus vaccination appeared imminent, a nationwide surveillance program was organized between October 1996 and October 1998 in the largest Argentine cities. Surveillance for disease burden, rotavirus detection, and rotavirus typing was undertaken at nine locations. Results showed rotavirus to be associated with 42% of diarrhea admissions. Although the prevalent G types changed from year to year, common G types were found in 96% of the cases and were usually associated with common P types. Uncommon G types, G9 and G5, were found at low prevalence and uncommon G/P combinations occurred at almost every study site. These data suggest that a rotavirus vaccine could substantially decrease the rotavirus disease burden in Argentina, but that introduction of a vaccine should be accompanied by a concurrent surveillance system. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:190 / 198
页数:9
相关论文
共 48 条
  • [1] Argüelles MH, 2000, J CLIN MICROBIOL, V38, P252
  • [2] Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial
    Bernstein, DI
    Sack, DA
    Rothstein, E
    Reisinger, K
    Smith, VE
    O'Sullivan, D
    Spriggs, DR
    Ward, RL
    [J]. LANCET, 1999, 354 (9175) : 287 - 290
  • [3] PROTECTION FROM ROTAVIRUS REINFECTION - 2-YEAR PROSPECTIVE-STUDY
    BERNSTEIN, DI
    SANDER, DS
    SMITH, VE
    SCHIFF, GM
    WARD, RL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (02) : 277 - 283
  • [4] PROTECTION CONFERRED BY NEONATAL ROTAVIRUS INFECTION AGAINST SUBSEQUENT ROTAVIRUS DIARRHEA
    BHAN, MK
    LEW, JF
    SAZAWAL, S
    DAS, BK
    GENTSCH, JR
    GLASS, RI
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (02) : 282 - 287
  • [5] USE OF SEROTYPE-SPECIFIC MONOCLONAL-ANTIBODIES TO STUDY THE EPIDEMIOLOGY OF ROTAVIRUS INFECTION
    BIRCH, CJ
    HEATH, RL
    GUST, ID
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1988, 24 (01) : 45 - 53
  • [6] DEVELOPMENT OF CANDIDATE ROTAVIRUS VACCINES
    BISHOP, RF
    [J]. VACCINE, 1993, 11 (02) : 247 - 254
  • [7] G and P genotyping of rotavirus strains circulating in France over a three-year period: Detection of G9 and P[6] strains at low frequencies
    Bon, F
    Fromantin, C
    Aho, S
    Pothier, P
    Kohli, E
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (04) : 1681 - 1683
  • [8] Castillo I., 1994, International Journal of Global Energy Issues, V6, P28
  • [9] Centers for Disease Control and Prevention (CDC), 1999, MMWR-MORBID MORTAL W, V48, P577
  • [10] Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants
    Clements-Mann, ML
    Makhene, MK
    Mrukowicz, J
    Wright, PF
    Hoshino, Y
    Midthun, K
    Sperber, E
    Karron, R
    Kapikian, AZ
    [J]. VACCINE, 1999, 17 (20-21) : 2715 - 2725